SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : son of T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (367)1/4/2000 12:51:00 PM
From: scaram(o)uche  Respond to of 673
 
>> I'd be curious as to what Rick's 'genomics' picks for
the year ahead might be. <<

GENXY, if I have to choose one at these market caps. Also like GZMO, of course, but more for ATIII than for SAGE.

Squawk box teaser on CNBC just a second ago, "biotech is hot, biotech CEOs tomorrow morning".

What 2000 thread?



To: Mike McFarland who wrote (367)1/4/2000 1:09:00 PM
From: LLCF  Respond to of 673
 
< hanging on awhile longer, .

No way I'm selling the top here... just 'blindly selling', I agree with you and am holding some PA.

DAK



To: Mike McFarland who wrote (367)1/7/2000 11:09:00 PM
From: tommysdad  Respond to of 673
 
<<(AXPH)
This blind Squirrel is hanging on awhile longer,
they've really been left behind on this genomics
rally>>

Pardon my ignorance here, but I'm not sure why AXPH would be considered a genomics play. True, this is "Arris + Sequana", but I don't believe any of the Sequanae survived.

At this point, I don't see AXPH as much more than an indirect combichem play, and not a very good one at that.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News